Amarin’s Vazkepa gets green light from SMC
Treatment will help reduce the risk of heart attacks and strokes for patients across Scotland
Read More
Tag: SMC
MSD’s Keytruda given go-ahead by SMC
Treatment concerns adults and adolescents with stage IIB or IIC melanoma skin cancer
Read More
Scottish Medicines Consortium recommends Merck’s Tepmetko
Therapy is the first oral MET inhibitor treatment option for certain advanced NSCLC adult patients
Read More
Scottish Medicines Consortium agrees to use of Rinvoq
Therapy will now treat adults across Scotland with moderate rheumatoid arthritis
Read More
SMC expands guidance for Lokelma to emergency care settings
New access to treatment involves adult patients with hyperkalaemia across Scotland
Read More
Jazz Pharmaceuticals receives SMC approval for reimbursement of Sativex
Therapy is for the treatment of spasticity due to multiple sclerosis
Read More
SMC approve Johnson & Johnson’s systemic light chain amyloidosis therapy
Newly diagnosed patients will become the first to access systemic light chain amyloidosis treatment in the UK
Read More
Cambridge Pharma promises to boost drug development
New facility opens on the Cambridge Research Park offering sterile finish
Read More
SMC approval welcome news for breast cancer patients
Trodelvy is accepted for use in mTNBC patients who have already received two or more systemic therapies
Read More
Tecentriq, Kesimpta lead latest SMC decisions
SMC was unable to accept Pfizer’s Vyndaqel for use in patients with transthyretin amyloidosis
Read More
SMC backs five new medicines for NHS use
Servier’s Lonsurf and AstraZeneca’s Calquence are among the positive decisions
Read More
SMC endorses Alexion’s Ultomiris
Committee also accepted Braftovi combination, Ledaga and Zejula for use by NHS Scotland in May decisions
Read More
- Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
- Alzecure shares new preclinical data on NeuroRestore ACD856 at AD/PD conference
- Samsung Bioepis signs partnership with Sandoz for next‑generation biosimilars
- Atrogi begins dosing first subjects in human trial of ATR-258
- R1 Therapeutics launches with $77.5m to advance hyperphosphatemia treatment
